Volume 48, Issue 3 (May 2003)

    Zaleplon and Driving Impairment

    (Received 5 October 2002; accepted 3 December 2002)

    Published Online: May

    CODEN: JFSOAD

      Format Pages Price  
    PDF Version 3 $25   ADD TO CART


    Abstract

    Zaleplon, a sedative-hypnotic, was identified in the blood of a subject arrested for impaired driving. Symptoms reported were those of central nervous system (CNS) depression. The zaleplon concentration was determined to be 0.13 µg/mL. Symptoms included slow movements and reactions, poor coordination, and lack of balance. Although no quantitative relationship between blood concentrations and degree of driving impairment is currently possible, it is reasonable to conclude that because of its specific activity as a sedative-hypnotic, blood concentrations consistent with doses exceeding therapeutic concentrations of zaleplon have the potential to cause impairment of psychomotor function, and would impair a person's level of consciousness and driving ability.


    Stock #: JFS2002357

    ISSN: 0022-1198

    DOI: 10.1520/JFS2002357

    ASTM International
    is a member of CrossRef.

    Author
    Title Zaleplon and Driving Impairment
    Symposium , 0000-00-00
    Committee E30